Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

698 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Sibbing D, et al. J Am Coll Cardiol. 2009 Mar 10;53(10):849-56. doi: 10.1016/j.jacc.2008.11.030. J Am Coll Cardiol. 2009. PMID: 19264241 Clinical Trial.
A point-of-care assay with similar predictive power would be of great value. METHODS: Between February 2007 and April 2008, a total of 1,608 consecutive patients with coronary artery disease and planned drug-eluting stent implantation were enrolled. ...The ADP-induc
A point-of-care assay with similar predictive power would be of great value. METHODS: Between February 2007 and April 2008, a
Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, O'Donoghue ML, Bernlochner I, Contant CF, Guo J, Sabatine MS, Schömig A, Neumann FJ, Kastrati A, Wiviott SD, Sibbing D. Hochholzer W, et al. Am Heart J. 2011 Sep;162(3):518-26.e5. doi: 10.1016/j.ahj.2011.06.005. Epub 2011 Aug 11. Am Heart J. 2011. PMID: 21884870 Clinical Trial.
METHODS: A variety of platelet function results was analyzed from 2 large cohorts of patients undergoing coronary intervention after loading with clopidogrel 600 mg (n = 2,533 and n = 1,996), a cohort of patients undergoing dose adaptation from 75 to 150 mg accordin …
METHODS: A variety of platelet function results was analyzed from 2 large cohorts of patients undergoing coronary intervention after …
Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting.
Bernlochner I, Mayer K, Morath T, Orban M, Schulz S, Schömig A, Braun S, Kastrati A, Sibbing D. Bernlochner I, et al. Thromb Haemost. 2013 Mar;109(3):517-24. doi: 10.1160/TH12-08-0552. Epub 2013 Jan 17. Thromb Haemost. 2013. PMID: 23328965
Thus, we aimed to determine the antiplatelet efficacy of prasugrel loading (LD) and maintenance dose (MD) treatment in a registry of patients with high PR levels on clopidogrel and a consecutive switch over to prasugrel in a setting of routine platelet functi …
Thus, we aimed to determine the antiplatelet efficacy of prasugrel loading (LD) and maintenance dose (MD) treatment in a registry of …
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.
Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Jüni P. Stettler C, et al. BMJ. 2008 Aug 29;337:a1331. doi: 10.1136/bmj.a1331. BMJ. 2008. PMID: 18757996 Free PMC article. Review.
REVIEW METHODS: Network meta-analysis with a mixed treatment comparison method to combine direct within trial comparisons between stents with indirect evidence from other trials while maintaining randomisation. ...Both drug eluting stents were associated with a decr …
REVIEW METHODS: Network meta-analysis with a mixed treatment comparison method to combine direct within trial comparisons between ste …
Drug-eluting stents is their future as bright as their past?
Kastrati A, Schömig A. Kastrati A, et al. J Am Coll Cardiol. 2007 Jul 10;50(2):146-8. doi: 10.1016/j.jacc.2007.04.028. Epub 2007 May 22. J Am Coll Cardiol. 2007. PMID: 17616298 No abstract available.
Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schömig A, Windecker S, Kastrati A. Stefanini GG, et al. Eur Heart J. 2012 May;33(10):1214-22. doi: 10.1093/eurheartj/ehs086. Epub 2012 Mar 24. Eur Heart J. 2012. PMID: 22447805
In addition, the risk of stent thrombosis was significantly reduced with biodegradable polymer DES vs. durable polymer SES (hazard ratio 0.56, 95% CI 0.35-0.90, P= 0.015), driven by a lower risk of very late stent thrombosis (hazard ratio 0.22, 95% CI 0.08-0.61, P= 0.004). …
In addition, the risk of stent thrombosis was significantly reduced with biodegradable polymer DES vs. durable polymer SES (hazard ratio 0.5 …
Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels.
Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schömig A; Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries (ISAR-SMART 3) Study Investigators. Mehilli J, et al. Eur Heart J. 2006 Feb;27(3):260-6. doi: 10.1093/eurheartj/ehi721. Epub 2006 Jan 9. Eur Heart J. 2006. PMID: 16401670 Clinical Trial.
METHODS AND RESULTS: A total of 360 patients undergoing percutaneous coronary intervention for de novo lesions in native coronary vessels with a diameter of <2.80 mm received randomly paclitaxel-eluting stents (n=180) or sirolimus-eluting stents (n=180). ...CONCL …
METHODS AND RESULTS: A total of 360 patients undergoing percutaneous coronary intervention for de novo lesions in native coronary ves …
Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting.
Koch W, Tiroch K, von Beckerath N, Schömig A, Kastrati A. Koch W, et al. Cytokine. 2003 Nov 21;24(4):161-71. doi: 10.1016/j.cyto.2003.08.004. Cytokine. 2003. PMID: 14572794
We investigated the possibility that single nucleotide polymorphisms of the genes encoding TNF-alpha (-863C/A, -308G/A), LT-alpha (252G/A), and IL-10 (-1082G/A, -819C/T, and -592C/A) are associated with the incidence of restenosis, death, or myo …
We investigated the possibility that single nucleotide polymorphisms of the genes encoding TNF-alpha (-863C/A, -308G/A), LT-al …
Validity of cardiac implantable electronic devices in assessing daily physical activity.
Pressler A, Danner M, Esefeld K, Haller B, Scherr J, Schömig A, Halle M, Kolb C. Pressler A, et al. Int J Cardiol. 2013 Sep 30;168(2):1127-30. doi: 10.1016/j.ijcard.2012.11.050. Epub 2012 Nov 30. Int J Cardiol. 2013. PMID: 23201084
METHODS: 73 ICD/CRT recipients (age 60 ± 20 years, 21% female) received a validated external accelerometer over a period of 7 days. ...A strong, significant intra-individual correlation (r>0.7) between the two measurements was observed in a majority …
METHODS: 73 ICD/CRT recipients (age 60 ± 20 years, 21% female) received a validated external accelerometer over a period of 7 …
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schömig A, Berger PB, Mehilli J; ISAR-REACT 4 Trial Investigators. Kastrati A, et al. N Engl J Med. 2011 Nov 24;365(21):1980-9. doi: 10.1056/NEJMoa1109596. Epub 2011 Nov 13. N Engl J Med. 2011. PMID: 22077909 Clinical Trial.
METHODS: Immediately before PCI, we randomly assigned, in a double-blind manner, 1721 patients with acute non-ST-segment elevation myocardial infarction to receive abciximab plus unfractionated heparin (861 patients) or bivalirudin (860 patients). ...
METHODS: Immediately before PCI, we randomly assigned, in a double-blind manner, 1721 patients with acute non-ST-segment elevation my …
698 results
Jump to page
Feedback